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Mouse embryonic stem (ES) cells rely on threonine as a
metabolic fuel. ES cells express the gene encoding threo-
nine dehydrogenase (TDH) at a 1,000-fold higher level
than any other mouse cell or tissue type. The mitochon-
drial TDH enzyme catalyzes the conversion of threonine
into acetyl-CoA and glycine. The former metabolite feeds
the TCA cycle, and the latter is consumed by the glycine
cleavage enzyme complex to fuel one carbon metabolism.
If compromised by nutritional, genetic or pharmacologi-
cal means, inhibition of TDH kills mouse ES cells. By
contrast, knockout mice lacking any TDH activity are
viable, fertile and exhibit no phenotypic deficits.
Were TDH essential to the growth of any human tumor,
one might predict that inhibitors of the enzyme would dis-
play favorable therapeutic utility. Unfortunately, among all
mammals - including primates - humans are unique in
being TDH-deficient. Proceeding with the idea that human
tumors might exist in some other form of metabolic spe-
cialization, Benjamin Tu and I have followed an acetyl-
CoA centric path in search of tumor-specific metabolic
vulnerabilities. Numerous clinical studies using 11C-acetate
PET imaging have reported tumor-enhanced uptake of
acetate. Three enzymes are capable of converting acetate
into acetyl-CoA; two of mitochondrial localization (ACSS1
and ACSS3), and a third that is nucleo-cytosolic (ACSS2).
The McKnight and Tu labs, working collaboratively with
the labs of Elizabeth Maher and Robert Bachoo, have
found that the nucleo-cytosolic ACSS2 enzyme is primarily
responsible for acetate uptake in cultured tumor cells and
human tumors.
Knockout mice lacking ACSS2 are viable, fertile and
devoid of obvious phenotypic deficits. When crossed with
either of two genetic models of hepatocellular cancer,
ACSS2-deficient mice exhibit a substantial reduction in
tumor burden. Proceeding with these observations, a drug
screen was performed in search of selective inhibitors of
the ACSS2 enzyme. The screen yielded ACSS2 inhibitors
that do not inhibit other acyl-synthetase enzymes, includ-
ing ACSS1 and ACSS3. These inhibitors have been
polished by medicinal chemistry to improve potency and
pharmacological properties. As expected from the genetic
ablation of ACSS2, potent ACSS2 inhibitors are well toler-
ated by mice and rats. Should it be the case that humans,
like mice, are not reliant on the ACSS2 enzyme, it is possi-
ble that chemical inhibitor of ACSS2 may be of use in
either the treatment or prevention of cancer.
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